Q&A: How does Gilenya/Tyzabri/Campath/Rituximab treat Multiple Sclerosis?

  • gilenya2Fingolimod (FTY720)/Gilenya
    • Functions: regulates migration of activated immune cells by activating S1P G-protein coupled receptors, leading to increased sequestering of lymphocytes influx into the lymph node.
    • FTY720: approved for treating for relapse remitting MS; phase II clinical trial showed suppression of relapse.
  • natalizumab-15900_1Natalizumab (anti-a4b1 antibody)/Tyzabri
    • Functions: blocking the a4b1 integrin expressed on activated lymphocytes, which a4b1 integrin is required to interact with VCAM-1 on endothelial cells for the activated cells to cross vasculature to the CNS.
  • Alemtuzumab (anti-CD52 antibody)
    • Functions: blocking CD-52 expressed on immune cells. Thus, it will deplete immune cells from circulation.
  • Anti-CD20 (Rituximab, Ocrelizumab)
    • Functions: blocking the CD-20 expressed on B cell, thus it will stop maturation of B cell into antibody secreting plasma cells.

Related: Immune modulating agents for treating MS